Current Affairs - International - Discussion

The United States Food and Drug Administration (FDA) has approved Lenacapavir, a groundbreaking long-acting HIV prevention injection developed by Gilead Sciences. Branded as Yeztugo, this medication is administered only twice a year and demonstrated an impressive 99.9% effectiveness in Phase 3 clinical trials. The approval marks a significant advancement in the field of HIV prevention, offering a more convenient and stigma-reducing alternative to daily pills or bimonthly injections. With this development, the U.S. becomes a frontrunner in adopting innovative biomedical tools aimed at improving public health outcomes and expanding access to long-term HIV prophylaxis options.